What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trial

View Full Paper

Ask AI

Bookmark

Authors

Subgroup analysis shows mitapivat significantly reduces transfusion burden in adults with alpha-thalassemia, highlighting its potential benefits.

A higher proportion of patients with α-thalassemia receiving mitapivat achieved transfusion reduction compared to placebo.
In the subgroup of α-thalassemia patients, 77.8% in the mitapivat arm achieved transfusion reduction response vs 0% in placebo.
Subgroup analysis included adult patients with α-thalassemia from the Phase 3 ENERGIZE-T trial randomized controlled trial.
Mitapivat may fulfill an unmet need for effective treatments in α-thalassemia, with significant implications for patient quality of life.

Kuo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Subgroup analysis shows mitapivat significantly reduces transfusion burden in adults with alpha-thalassemia, highlighting its potential benefits.